Global Pharma Digest: Key Developments (July 1–25, 2025): Quantum computing, preemptive tariff measures, and cross-continental deals take center stage

The “Global Business Monitor: Industry and Regional Trends” project has released its latest Pharmaceutical Companies Digest, covering major industry developments between July 1 and 25, 2025.

The report examines critical operational and strategic moves across the sector, including:

1. Quantum leap in drug discovery
   The Danish government and Novo Nordisk have invested 40€ million each in Magne – Northern Europe’s most powerful quantum computer, built on Microsoft’s architecture to enhance R&D processes, chemical modeling and logistics. (Source: Pharmaceutical Bulletin)
2. Preemptive moves by manufacturers against potential U.S. tariffs
   Anticipating potential drug import tariffs, AstraZeneca unveiled a historic $50 billion investment plan (2025–2030) to expand U.S. manufacturing. The centerpiece is a new active pharmaceutical ingredient plant – the company’s most expensive facility ever. (Source: Fierce Pharma)
3. Cross-continental M&A activity reshaping market dynamics
   Merck acquired Verona Pharma for $10 billion, gaining rights to an innovative lung therapy. This marks 2025’s second-largest biopharma deal after J&J’s $14.6B acquisition, filling Merck’s pipeline ahead of its blockbuster drug Keytruda patent cliff (Source: Pharmaceutical Bulletin).

For a more detailed analysis of these developments and other key trends, access the full Digest (in Russian) via the “Global Business Monitor: Industry and Regional Trends” project.